S-1838-119
Passed Senate with an amendment by Voice Vote. (text of amendment in the nature of a substitute: CR S4495-4496)
Sponsored by John Hickenlooper (D-CO)
What it does
This bill would amend the Public Health Service Act to formally authorize the NIH's INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. It would direct the NIH Director to carry out a coordinated program of research, clinical trials, training, and investigation focused on Down syndrome and conditions that frequently occur alongside it, such as Alzheimer's disease and autoimmune disorders. The bill would also require the NIH Director to submit biennial progress reports to Congress and consult with patient advocates and other stakeholders.
Who benefits
The approximately 200,000 Americans currently living with Down syndrome and their families. Researchers and academic institutions that would receive NIH funding and training support. Pharmaceutical and biotech companies developing therapies for Down syndrome and co-occurring conditions. Patients with Alzheimer's disease and autoimmune conditions, who may benefit indirectly from research into the elevated prevalence of those conditions in people with Down syndrome. Patient advocacy organizations that would gain a formal consultative role.
Who is hurt
Researchers and institutions working on other NIH-funded conditions who may face increased competition for limited NIH resources if funding is redirected. Taxpayers who bear the cost of any new appropriations, though the bill does not specify a funding amount. Other disease research communities that lack a comparable statutory authorization and may be disadvantaged in NIH priority-setting.
Supporters argue
Supporters argue that Down syndrome affects roughly 1 in 700 births in the United States and that individuals with the condition face dramatically elevated risks of Alzheimer's disease — with nearly all developing the pathology by age 40 — yet the condition has historically been underfunded relative to its prevalence and complexity. They contend that formally authorizing the INCLUDE Project in statute ensures programmatic continuity, prevents the initiative from being administratively discontinued, and creates accountability through mandatory congressional reporting.
Opponents argue
Opponents argue that Congress should not single out individual diseases for statutory research mandates, as doing so distorts NIH's merit-based peer review process and sets a precedent that favors conditions with effective advocacy networks over those with equal or greater public health burden. They contend that the INCLUDE Project already operates as an NIH initiative without statutory authorization, meaning the bill adds bureaucratic reporting requirements and potential rigidity without demonstrably increasing research output or funding.
Constitutional context
Congress has broad authority to fund biomedical research through the Taxing and Spending Clause (Art. I, §8, cl. 1) and to regulate activities with a substantial effect on interstate commerce under the Commerce Clause (Art. I, §8, cl. 3). Directing NIH to conduct a specific research program is a well-established exercise of these powers and does not raise significant constitutional questions under existing doctrine.
Checks and balances
The Executive Branch (NIH/HHS) gains a formal statutory mandate to run this program; Congress retains oversight through mandatory biennial reports to the relevant House and Senate committees and controls funding levels through the annual appropriations process.
Historical precedent
Congress has previously authorized disease-specific NIH research programs by statute, including the National Alzheimer's Project Act (2011), which similarly directed coordinated federal research and required periodic reports to Congress.